Suppr超能文献

全球耐药结核病概述。

Overview of drug-resistant tuberculosis worldwide.

作者信息

Velayati Ali A, Farnia Parissa, Farahbod Amir M

机构信息

Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S161. doi: 10.1016/j.ijmyco.2016.09.066. Epub 2016 Nov 11.

Abstract

Even in the 21st century, we are losing the battle against eradication of tuberculosis (TB). In 2015, 9.6 million people were estimated to have fallen ill with TB, of which 1.5 million people died. This is the real situation despite the well-structured treatment programs and availability of effective treatment options since the 1950s. The high mortality rate has been associated with other risk factors, such as the HIV epidemic, underlying diseases, and decline of socioeconomic standards. Furthermore, the problem of drug resistance that was recognized in the early days of the chemotherapeutic era raises serious concerns. Although resistance to a single agent is the most common type, resistance to multiple agents is less frequent but of greater concern. The World Health Organization estimated approximately 5% of all new TB cases involved multidrug-resistant (MDR)-TB. The estimation for MDR-TB is 3.3% for new cases, and 20.5% for previously treated cases. Failure to identify and appropriately treat MDR-TB patients has led to more dangerous forms of resistant TB. Based on World Health Organization reports, 5% of global TB cases are now considered to be extensively drug resistant (XDR), defined as MDR with additional resistance to both fluoroquinolones and at least one second-line injectable drug. XDR-TB had been reported by 105 countries by 2015. An estimated 9.7% of people with MDR-TB have XDR-TB. More recently, another dangerous form of TB bacillus was identified, which was named totally drug resistant (TDR-TB) or extremely drug resistant TB. These strains were resistant to all first- and second-line anti-TB drugs. Collectively, it is accepted that 2% of MDR-TB strains turn to be TDR-TB. This number, however, may not reflect the real situation, as many laboratories in endemic TB countries do not have proper facilities and updated protocols to detect the XDR or TDR-TB strains. Nevertheless, existing data emphasize the need for additional control measures, such as new diagnostic methods, better drugs, and more effective vaccines to prevent the spread of these strains around the world.

摘要

即便到了21世纪,我们仍在抗击结核病(TB)的战斗中节节败退。2015年,据估计有960万人罹患结核病,其中150万人死亡。尽管自20世纪50年代起就有结构完善的治疗方案且可获得有效的治疗选择,但这就是实际情况。高死亡率与其他风险因素相关,如艾滋病毒流行、基础疾病以及社会经济标准下降。此外,在化疗时代早期就已被认识到的耐药问题引发了严重担忧。虽然对单一药物耐药是最常见的类型,但对多种药物耐药的情况较少见但更令人担忧。世界卫生组织估计,所有新结核病病例中约5%涉及耐多药(MDR)结核病。新病例中耐多药结核病的估计比例为3.3%,既往治疗病例中为20.5%。未能识别和妥善治疗耐多药结核病患者导致了更危险的耐药结核病形式。根据世界卫生组织的报告,全球结核病病例的5%现在被认为是广泛耐药(XDR)结核病,定义为对氟喹诺酮类药物和至少一种二线注射用药物均耐药的耐多药结核病。到2015年,已有105个国家报告了广泛耐药结核病。估计9.7%的耐多药结核病患者患有广泛耐药结核病。最近,又发现了另一种危险的结核杆菌形式,被称为完全耐药(TDR)结核病或极端耐药结核病。这些菌株对所有一线和二线抗结核药物均耐药。总体而言,人们公认2%的耐多药结核菌株会转变为完全耐药结核病。然而,这个数字可能无法反映实际情况,因为结核病流行国家的许多实验室没有适当的设施和更新的方案来检测广泛耐药或完全耐药结核菌株。尽管如此,现有数据强调需要采取额外的控制措施,如新的诊断方法、更好的药物和更有效的疫苗,以防止这些菌株在全球传播。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验